Antibacterial activity of heterogeneous TiO2 and ZnO nanoparticles against Gram-positive and Gram-negative bacterial pathogens
Keywords:
TiO2/ZnO nanoparticles, Hospital-acquired infections, Antibacterial activity, Bacteriostatic agent, Bactericidal agent, Biomedical Product, Biomaterial, NanomaterialAbstract
Hospital-acquired infections (HAIs) are responsible for over 40% of cases in acute-care hospitals and commonly associated with catheters-associated urinary tract infections (CAUTIs). Current nanotechnology approach focus on improving the aseptic procedures for medical devices and manage the HAIs risk. TiO2 and ZnO nanoparticles (NPs) have been widely reported independently, to have a photocatalytic killing potential. The present study evaluates the antibacterial activity of heterojunction between TiO2 and ZnO NPs on several types bacterial pathogens model including Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The antibacterial screening test on TiO2/ZnO nanoparticles (NPs) were done under dark and light conditions with different molar ratio 25T75Z, 50T50Z and 75T25Z according to Clinical Laboratory Standards Institute (CLSI) guidelines MO2-A11. ZnO and TiO2/ZnO (25T75Z and 50T50Z) NPs at the highest concentration (1000μg/μL) showed mean diameters of the zones of inhibition (mm); (12.5 ± 0.58), (12.13 ± 0.85), and (7.25 ± 1.44) in dark condition. Increment in inhibition zones was obtained under light condition; (21.38 ± 0.48), (17.50 ± 1.0), and (12.38 ± 1.80). Findings from this study highlights the heterogeneous TiO2 and ZnO NPs could become a promising bacteriostatic and/or bactericidal agent to combat against the HAIs.References
HPA (2012a). English National Point Prevalence Survey on Healthcare- Associated Infections and Antimicrobial Use, 2011: Preliminary Data. London: Health Protection Agency.
Donlan RM. Biofilms and device-associated infections. Emerging infectious diseases. 2001 Mar;7(2):277.
Donlan RM. Biofilms on central venous catheters: is eradication possible?. InBacterial biofilms 2008 (pp. 133-161). Springer Berlin Heidelberg.
Rutala WA, Weber DJ. Disinfection and sterilization: an overview. American journal of infection control. 2013 May 31;41(5):S2-5.
Rajh T, Dimitrijevic NM, Bissonnette M, Koritarov T, Konda V. Titanium dioxide in the service of the biomedical revolution. Chemical reviews. 2014 Aug 29;114(19):10177-216.
Hong H, Shi J, Yang Y, Zhang Y, Engle JW, Nickles RJ, Wang X, Cai W. Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. Nano letters. 2011 Aug 10;11(9):3744-50.
Liu Y. Application of Gadolinium-Doped Zinc Oxide Quantum Dots for Magnetic Resonance and Fluorescence Imaging. InMultifunctional Nanoprobes 2018 (pp. 65-79). Springer, Singapore.
Ansari SA, Husain Q, Qayyum S, Azam A. Designing and surface modification of zinc oxide nanoparticles for biomedical applications. Food and Chemical Toxicology. 2011 Sep 1;49(9):2107-15.
Yuan Q, Hein S, Misra RD. New generation of chitosan-encapsulated ZnO quantum dots loaded with drug: synthesis, characterization and in vitro drug delivery response. Acta Biomaterialia. 2010 Jul 1;6(7):2732-9.
Weir A, Westerhoff P, Fabricius L, Hristovski K, Von Goetz N. Titanium dioxide nanoparticles in food and personal care products. Environmental science & technology. 2012 Feb 8; 46(4):2242-50.
Fan Z, Lu JG. Zinc oxide nanostructures: synthesis and properties. Journal of nanoscience and nanotechnology. 2005 Oct 1;5 (10):1561-73.
Mao, Y., Park, T. J., & Wong, S. S. (2005). Synthesis of classes of ternary metal oxide nanostructures. Chemical Communications, (46), 5721-5735.
Yalcinkaya F, Lubasova D. Quantitative evaluation of antibacterial activities of nanoparticles (ZnO, TiO2, ZnO/TiO2, SnO2, CuO, ZrO2, and AgNO3) incorporated into polyvinyl butyral nanofibers. Polymers for Advanced Technologies. 2017 Jan 1;28(1):137-40.
Jašková V, Hochmannová L, Vytřasová J. TiO2 and ZnO nanoparticles in photocatalytic and hygienic coatings. International journal of photoenergy. 2013 Feb 24;2013.
Talebian N, Doudi M, Mogoei H. Antibacterial activities of sol–gel derived ZnO-multilayered thin films: p-NiO heterojunction layer effect. Journal of Sol-Gel Science and Technology. 2015 Jun 1;74(3):650-60.
Widiarti N, Sae JK, Wahyuni S. Synthesis CuO-ZnO nanocomposite and its application as an antibacterial agent. InIOP Conference Series: Materials Science and Engineering 2017 Feb (Vol. 172, No. 1, p. 012036). IOP Publishing.
Xu JW, Gao ZD, Han K, Liu Y, Song YY. Synthesis of magnetically separable Ag3PO4/TiO2/Fe3O4 heterostructure with enhanced photocatalytic performance under visible light for photoinactivation of bacteria. ACS applied materials & interfaces. 2014 Aug 27;6(17):15122-31.
Edition AS. CLSI document M02-A11. Wayne, PA: Clinical and Laboratory Standards Institute. 2012;32(1):76.
Jesline A, John NP, Narayanan PM, Vani C, Murugan S. Antimicrobial activity of zinc and titanium dioxide nanoparticles against biofilm-producing methicillin-resistant Staphylococcus aureus. Applied Nanoscience. 2015 Feb 1;5(2):157-62.
Joe A, Park SH, Shim KD, Kim DJ, Jhee KH, Lee HW, Heo CH, Kim HM, Jang ES. Antibacterial mechanism of ZnO nanoparticles under dark conditions. Journal of Industrial and Engineering Chemistry. 2017 Jan 25;45:430-9.
Hirota K, Sugimoto M, Kato M, Tsukagoshi K, Tanigawa T, Sugimoto H. Preparation of zinc oxide
ceramics with a sustainable antibacterial activity under dark conditions. Ceramics International. 2010 Mar 31;36(2):497-506.
Kirkinezos IG, Moraes CT. Reactive oxygen species and mitochondrial diseases. InSeminars in cell & developmental biology 2001 Dec 31 (Vol. 12, No. 6, pp. 449-457). Academic Press.
Clifton LA, Skoda MW, Daulton EL, Hughes AV, Le Brun AP, Lakey JH, Holt SA. Asymmetric phospholipid: lipopolysaccharide bilayers; a Gram-negative bacterial outer membrane mimic. Journal of The Royal Society Interface. 2013 Dec 6;10(89):20130810.
Santos RS, Figueiredo C, Azevedo NF, Braeckmans K, De Smedt SC. Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: Towards advanced delivery of antibiotics. Advanced drug delivery reviews. 2017 Dec 14.Egan, A. J. (2018). Bacterial outer membrane constriction. Molecular microbiology.
Bajaj H, Acosta Gutierrez S, Bodrenko I, Malloci G, Scorciapino MA, Winterhalter M, Ceccarelli M. Bacterial outer membrane porins as electrostatic nanosieves: exploring transport rules of small polar molecules. ACS nano. 2017 May 12;11(6):5465-73
Auer GK, Weibel DB. Bacterial cell mechanics. Biochemistry. 2017 Jul 11;56(29):3710-24
Downloads
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
